Regulatory

Mar 28, 2017
Jill Wechsler outlines how the new FDA commissioner tasked with curbing regulation, speeding approvals—and collecting more fees to do it.
Mar 22, 2017
FDA efforts to speed more new generic drugs to market probably won’t do much to reduce high drug prices, writes Jill Wechsler.
Mar 16, 2017
NICE and NHSE have been grappling with the issue of affordability. Leela Barham reports.
Mar 14, 2017
Thomas Christensen outlines some of his lessons learned for first time OPDP submissions, promotional material, and labelling.
Mar 14, 2017
Trump’s choice for FDA commissioner faces drug pricing, regulatory, and approval challenges.
Mar 07, 2017
An FDA Memo addressing First Amendment legal issues regarding off-label use of medical products falls short of the necessary clarity, write Jamie Kendall and Alexandra Schulz.
Mar 06, 2017
Pharmaceutical Executive
Attack on treaties and imports threatens international operations.
Feb 21, 2017
The risk of non-compliance with export controls, and the associated civil and criminal penalties, are very real given the sensitive and global nature of the biopharmaceutical industry’s work. This article outlines steps companies should take to ensure compliance with export controls.
Feb 10, 2017
In promising to expedite and simplify the FDA approval process, Donald Trump fails to take account of industry's appreciation an efficient, rigorous FDA regulatory system, writes Jill Wechsler.
Feb 06, 2017
Pharmaceutical Executive
Congress is poised to tackle exorbitant drug prices through health reform and FDA legislation.
native1_300x100
lorem ipsum